Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Carboplatin/paclitaxel

Carboplatin/paclitaxel Reactions 1680, p83 - 2 Dec 2017 Febrile neutropenia, neuropathy and anorexia: 3 case reports In a retrospective study of 52 patients, three patients [ages and sexes not stated] were described, who developed febrile neutropenia, neuropathy or anorexia during treatment with carboplatin and paclitaxel [durations of treatment to reactions onsets and outcomes not stated]. Patient 1: a patient developed febrile neutropenia during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 febrile neutropenia. Patient 2: a patient developed neuropathy during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 neuropathy. Patient 3: a patient developed anorexia during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Carboplatin/paclitaxel

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Download PDF
1 page

Carboplatin/paclitaxel

Abstract

Reactions 1680, p83 - 2 Dec 2017 Febrile neutropenia, neuropathy and anorexia: 3 case reports In a retrospective study of 52 patients, three patients [ages and sexes not stated] were described, who developed febrile neutropenia, neuropathy or anorexia during treatment with carboplatin and paclitaxel [durations of treatment to reactions onsets and outcomes not stated]. Patient 1: a patient developed febrile neutropenia during treatment with carboplatin and paclitaxel. The patient, who had...
Loading next page...
1
 
/lp/springer_journal/carboplatin-paclitaxel-09hJZU3GL7

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-39014-x
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p83 - 2 Dec 2017 Febrile neutropenia, neuropathy and anorexia: 3 case reports In a retrospective study of 52 patients, three patients [ages and sexes not stated] were described, who developed febrile neutropenia, neuropathy or anorexia during treatment with carboplatin and paclitaxel [durations of treatment to reactions onsets and outcomes not stated]. Patient 1: a patient developed febrile neutropenia during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 febrile neutropenia. Patient 2: a patient developed neuropathy during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC 5 and IV infusion of paclitaxel 175 mg/m on day 1. The cycle was repeated every 21 days. Subsequently, the patient developed grade 3 neuropathy. Patient 3: a patient developed anorexia during treatment with carboplatin and paclitaxel. The patient, who had progression of urothelial carcinoma after gemcitabine and cisplatin chemotherapy, received IV infusion of carboplatin AUC

Journal

Reactions Weekly – Springer Journals

Published: Dec 2, 2017

There are no references for this article.